clinical trial

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) experienced a severe drop on Friday, plummeting almost 60% from $52 to $21, as competitor Novo Nordisk (NYSE:NVO) published trial results for monlunabant, a cannabinoid receptor 1 (CB1) inverse agonist. Novo Nordisk shares also traded down roughly 5.5...

Irish psychedelic biotech firm GH Research PLC (NASDAQ:GHRS) reported its financial results for the second quarter ended June 30, 2024. Q2 2024 Financial Highlights Cash, cash equivalents, other financial assets and marketable securities were $204.5 million as of June 30, 2024, compared to cash,...

SciSparc Ltd. (NASDAQ:SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel. What Happened The Israeli specialty clinical-stage...

The National Institutes of Health (NIH) recently said it will fund clinical trials to exam the safety and efficacy of psychedelic-assisted therapy in older adults with chronic pain, reported Marijuana Moment. According to NIH's Wednesday notice, it intends to direct $8.4 million toward research on...

SciSparc Ltd. (NASDAQ:SPRC) announced on Friday that it has enrolled the first patient in the company's clinical trial assessing the efficacy and safety of its cannabidiol (CBD) – based drug for the treatment of children with autism spectrum disorder. SCI-210 is a combination of CBD and...

The NFL is teaming up with Canadian researchers to delve into the potential of cannabidiol (CBD) for pain management and neuroprotection from concussions, both significant concerns for its players. This Phase 1 trial marks a first step in exploring the non-intoxicating cannabinoid's therapeutic...

Awakn Life Sciences (OTC: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has entered into a global licensing agreement with LTS Lohmann Therapie-Systeme AG. Headquartered in Andernach, Germany, LTS...

The quest to advance psychedelic medicine in Canada received a big boost today. The Minister of Mental Health and Addictions, Carolyn Bennett, announced an investment of nearly $3 million through the Canadian Institutes of Health Research. This funding will support three clinical...

Psychedelics biotech company Cybin Inc. (NYSE: CYBN) shared progress updates for its two lead clinical development programs: proprietary deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD) and proprietary deuterated DMT compound CYB004 for the...

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a No Objection letter and is set to proceed with the first-ever Phase 2a clinical trial on the magic...

Veru Inc. (NASDAQ: VERU) shares could gap-open lower on Thursday following a negative Food and Drug Administration Panel verdict for its COVID-19 treatment candidate. What Happened: Miami, Florida-based Veru announced late on Wednesday that FDA’s Pulmonary-Allergy Drugs Advisory Committee...

Clinical stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient (drug delivery) technology, with topline results expected in the first half of 2023....

Cannabinoid-focused biopharmaceutical company Greater Cannabis Company, Inc. (OTC: GCAN) has submitted a clinical trial application to the Israel Ministry of Health for approval of Phase 2 clinical trial for its novel neuropsychiatric cannabinoid therapy. The company seeks to conduct a Phase 2...

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin a Phase 1 clinical trial in 2022’s fourth quarter. The decision to focus research on...

Zelira Therapeutics (OTC: ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is about to begin a first-ever clinical trial of its own proprietary pain formula for the treatment of diabetic nerve pain...